tbuckley/cabot-search huggingface dataset:
Comparison of the simulation treatment planning of FLT and FDG PET/CT in contouring the biologic tumor volume in patients with thoracic esophageal carcinoma.
Authors: D. Han, J. Yu, G. Zhang, Z. Fu, X. Zhong, W. Yang
Journal: Journal of Clinical Oncology (2010)

e14554 Background: Use the optimal method of 3-deoxy-3-18F- fluorothymidine (FLT) PET/CT, which was determined by pathologic examination after operation to delineate biological tumor volume in thoracic esophageal carcinoma and make treatment planning for simulation, then compare with that of 18F-fluorodeoxyglucose (FDG). Methods: 24 patients with esophageal squamous cell carcinoma detected by FLT and FDG PET/CT were enrolled. We used Treatment Planning System to compare the simulation treatment planning based on the optimal threshold of FLT and FDG PET/CT, respectively. According to the same standard expanded GTV to CTV and PTV. The radiation dose was prescribed as 60 Gy in 30 fractions with conformal or intensity modulated radiotherapy technique, the same patient using the same radiotherapy technique such as a five-beam CRT or seven-field IMRT. Results: All of the treatment planning met with >90% of the PTV covered by the prescription isodose line and global hotspot of less than 15%. In the Table, we list the parameters of both FLT and FDG PET/CT planning. The difference in V20 of bilateral lung, V40 of heart and maximal dose received by spinal cord between FLT and FDG were not significantly. While, the values in MLD, V5, V10, V30, V40 and V50 of bilateral lung, MHD, and V30 of heart on FLT PET/CT based planning were significantly lower than that of FDG. Conclusions: FLT PET/CT-based treatment planning brought potential benefits to some OARs such as lungs and heart. Comparison of FLT and FDG PET/CT-based DVH Mean ± SD FLT PET/CT FDG PET/CT t P GTV (cm3) 29.03 ± 36.31 33.05 ± 42.03 -2.619 0.016 CTV (cm3) 244.22 ± 161.94 257.01 ± 160.68 -3.532 0.002 PTV (cm3) 351.29 ± 214.48 379.85 ± 222.00 -4.010 0.001 Total lung V5 (%) 66.1 ± 23.2 69.6 ± 22.8 -5.442 0.000 V10 (%) 49.7 ± 19.1 53.3 ± 19.0 -4.001 0.001 V20 (%) 22.5 ± 6.9 24.0 ± 5.7 -1.601 0.124 V30 (%) 9.7 ± 6.0 11.2 ± 5.4 -2.637 0.015 V40 (%) 4.7 ± 3.3 6.0 ± 4.0 -3.967 0.001 V50 (%) 2.4 ± 1.6 3.2 ± 1.9 -4.842 0.000 MLD (cGy) 1309.1 ± 435.5 1438.4 ± 455.7 -5.109 0.000 Heart V30 (%) 39.7 ± 17.9 43.2 ± 19.1 -3.198 0.004 V40 (%) 18.9 ± 9.7 21.3 ± 11.2 -1.553 0.135 MHD (cGy) 2450.7 ± 886.2 2591.0 ± 882.2 -3.098 0.005 Max cord (cGy) 4257.0 ± 201.1 4261.7 ± 208.2 -0.122 0.904 No significant financial relationships to disclose.
Association of Raynaud's phenomenon after bleomycin etoposide cisplatin (BEP) chemotherapy for testicular cancer (TC) with accelerated atherosclerosis.
Authors: R. Altena, H. Boer, C. Meijer, J. Nuver, A. M. van Roon, N. Zwart, E. De Vries, J. D. Lefrandt, A. J. Smit, J. A. Gietema
Journal: Journal of Clinical Oncology (2011)

4631 Background: Cross-sectional studies showed that treatment with BEP for TC causes a higher rate of cardiovascular disease. We investigated longitudinal changes in clinical and vascular parameters, to explore their role as early biomarkers for accelerated atherosclerosis. Methods: In consecutive TC patients (pts), cardiovascular morbidity, risk factors, plasma markers for endothelial activation (soluble inter cellular adhesion molecule [sICAM-1], von Willebrand factor [vWF]) and inflammation (high sensitivity C reactive protein [hsCRP]), and carotid intima media thickness (IMT; a subclinical atherosclerosis marker) were evaluated twice after BEP completion. Results: 50 pts underwent evaluations median 11 months and 6.5 years after BEP. During follow-up 2% had clinical cardiovascular morbidity; 28% had secondary Raynaud’s phenomenon. sICAM-1 and IMT increased (Table). At 6.5 years, IMT in TC pts equalled healthy males (n=45, median 0.59 mm [0.38-0.97]; p=0.93). In linear regression the age-related IMT increase was higher in TC pts (b=0.09 [SE=0.02], P<0.0001] than controls [b=0.06 [SE=0.02], P=0.003). Changes in IMT related to increases in serum lipids. Pts with Raynaud’s phenomenon had a higher age-related IMT increase (Raynaud: b=0.12 [SE=0.004], P=0.009; no Raynaud: b=0.006 [SE=0.002], P=0.002). Conclusions: Subclinical signs for atherosclerosis increase during follow-up after BEP for TC, with an accelerated age-related IMT progression compared to controls. The relationship between IMT and Raynaud’s phenomenon suggests that this symptom may be a clinical biomarker to identify survivors with augmented atherosclerosis, who may benefit from intervention. 11 months (8-15) 6.5 years (3.2-10.1) Median Range N abnormal Median Range N abnormal Blood pressure Systolic mmHg 125 100–170 3 124 100–180 13 Diastolic 74 60–100 80* 60–105 Body mass index kg/m2 25.3 18.9–38.0 4 25.5 20.2–41.7 7 Cholesterol mmol/L 4.7 3.2–7.8 0 4.8 3.4–7.3 6 Glucose mmol/L 4.7 2.6–5.8 0 5.5* 3.6–7.4 1 sICAM-1 ng/mL 373 159–727 423* 260–823 vWF % 87 52–237 99 37–204 hsCRP mg/L 0.7 0.2–8.9 0.8 0.2–4.7 IMT mm 0.53 0.41–0.90 0.59* 0.44–0.94 * P < 0.05, Wilcoxon signed rank
<i>BRAF</i>, <i>NRAS</i>, and <i>KIT</i> mutational analysis of spindle cell melanoma.
Authors: S. J. Dorkhom, J. Kim, A. J. F. Lazar, M. A. Davies, J. Homsi, N. E. Papadopoulos, W. Hwu, A. Y. Bedikian, S. E. Woodman, S. P. Patel, P. Hwu, K. B. Kim
Journal: Journal of Clinical Oncology (2011)

8589 Background: Spindle cell melanoma and its variant desmoplastic melanoma (DM) are a rare but distinct subset of malignant melanomas, and their genomic aberration have not been reported. Insight into these aberrations can help guide management, which has also not been outlined. We examined the frequencies of BRAF , NRAS and KIT mutations in spindle cell melanoma in this retrospective study. Methods: We searched in our institutional database at The University of Texas M.D. Anderson Cancer Center for patients with a diagnosis of pure spindle cell type melanoma (excluding the mixed type with spindle cells) whose tumors were analyzed for BRAF (exon 15 hotspot), NRAS (exons 1 and 2 hotspots) and KIT (exons 11, 13 and 17) mutation. The genomic sequencing analyses were performed with pyrosequencing, a PCR-based DNA sequencing technique. Results: We identified 24 patients with spindle cell melanoma, of which 10 patients had a diagnosis of DM, whose tumor were analyzed for at least 1 of the 3 genes. The mean age of the patients was 57 years, and fifteen (62.5%) of these patients were male. The median Breslow thickness was 2.8 mm, and the most common site of the primary melanoma was the trunk, followed by the head and neck region. BRAF, NRAS and KIT genomic sequencing was performed successfully in 20, 18 and 14 patients, respectively. Among the 20 melanomas with completed BRAF sequencing analysis, 6 (30%) harbored a mutation, of which 5 (83%) were V600E and 1 (17%) was V600R. None of the melanomas harbored NRAS or KIT mutation. Conclusions: This is the first report to note the genomic aberrations in spindle cell melanoma. As in the other common types of melanoma, V600 BRAF mutation is the most common mutation in spindle cell melanoma. However, unlike the other common subtypes, we did not identify any NRAS in the 18 patients analyzed. Also, despite the association of DM with intense sun damage, KIT mutation was not seen in 14 patients, 5 of which were DM. Larger studies are needed to further validate the mutational prevalence of BRAF, NRAS and KIT, but these latter two are likely to be very rare or absent. This information can hopefully lead to more prudent management and treatment decisions.
A double-blind, randomized, multicenter study regarding the effects of solution for gemcitabine on frequency and degree of vascular pain in patients with cancer.
Authors: H. Nagai, H. Yasuda, M. Kanai, T. Nishimura, T. Kitano, S. Matsumoto, Y. Mori, H. Ishiguro, Y. Kakudo, H. Sato, T. Yamaguchi, S. Takashima, K. Nakata, M. Kobayashi, T. Terada, T. Sasaki, T. Mio, M. Mishima, K. Yanagihara, M. Fukushima
Journal: Journal of Clinical Oncology (2011)

e19642 Background: Gemcitabine is an active anticancer drug approved for various kinds of cancers and has relatively few adverse events except for bone marrow toxicity, but we have sometimes experienced vascular pain during intravenous administration of gemcitabine. In retrospective analysis, we reported that the use of 5% glucose solution for dissolution of gemcitabine decreased frequency of vascular pain compared with that of saline solution for. However, there were no reports which demonstrated the difference in frequencies of vascular pain between 5% glucose solution and saline for gemcitabine dissolution. Therefore, we conducted this double-blind randomized study to compare the frequency and degree of vascular pain during administration of gemcitabine between them. Methods: Ninety patients were enrolled in a double-blind, randomized, crossover, and multicenter study from July 2009 to June 2010. The primary endpoint was frequency of vascular pain, and the secondary endpoints were degree and duration of vascular pain. Zero to 10 numerical scale was used to estimate the degree of vascular pain during administration of gemcitabine. Performance of this study was approved by ethic committee in Tohoku University (ID:2008-471) and Kyoto University (ID:C-295). Results: Eighty-seven patients were randomly assigned, and we used decentralized robust method for analysis of data. Frequency of vascular pain was significantly decreased in 5% glucose solution compared with that in saline solution (40% versus 63%, p<0.001). Degree of vascular pain was also relieved in 5% glucose solution compared with that in saline solution (pain score 1.3 versus 2.7, p<0.001). There was no significant statistic difference in duration of vascular pain between 5% glucose solution and saline solution (21 minutes versus 18 minutes, p=0.420). Conclusions: The use of 5% glucose solution for dissolution of gemcitabine significantly decreased the frequency and relieved the degree of vascular pain compared with those of saline solution. Gemcitabine may prefer to be dissolved with 5% glucose solution. ICMJE number, UMIN000001827.
CD30 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Correlates with Non-GCB Subtype but Does Not Have Prognostic Impact in Patients Treated with First Line R-CHOP/R-CHOP-like
Authors: Maria Queralt Salas, Fina Climent, Eva Domingo Domenech, Santiago Mercadal, Viviana Paredes, Ana Carla Oliveira, Carmen Aguilera, Esmeralda de la Banda, Anna Lucas, Nadia Garcia, Cristina Baca, Alberto Fernandez de Sevilla, Anna Sureda, Eva Gonzalez Barca, Maria Lutgarda Riasol
Journal: Blood (2016)
CDC4 and NOTCH1 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia and T Cell Non-Hodgkin’s Lymphoma; a Japan Association of Childhood Leukemia Study Group.
Authors: Myoung-ja Park, Tomohiko Taki, Nobuhiro Suzuki, Megumi Oda, Keiko Yagi, Ryoji Kobayashi, Juniti Hara, Keizo Horize, Yasuhide Hayashi
Journal: Blood (2007)
Effect of body mass index in patients undergoing resection for gastric cancer: A single-center U.S. experience.
Authors: Joyce Wong, Shams Rahman, Nadia Saeed, Hui-Yi Lin, Khaldoun Almhanna, Ravi Shridhar, Sarah Hoffe, Kenneth Meredith
Journal: Journal of Clinical Oncology (2013)

25 Background: With the rise of obesity in the U.S., the impact of body mass index (BMI) on surgical outcomes and survival in gastric cancer remains undetermined. Methods: An IRB-approved, prospectively-maintained institutional database of patients referred for surgical evaluation of gastric cancer was reviewed. Patients were stratified according to BMI: &lt;18.5 (underweight), 18.5-25 (normal weight), 25.1-30 (overweight), and &gt;30 (obese). Clinicopathologic factors and overall survival (OS) were analyzed using polytomous regression, Pearsons correlation and Kaplan Meier when appropriate. Results: From 1997-2012, 222 patients underwent exploration for gastric adenocarcinoma. Of these, 186 (84%) patients had BMI recorded: 9 (5%) with BMI&lt;18.5, 72 (39%) 18.5-25, 62 (33%) 25.1-30, and 43 (23%) &gt;30. 135 (73%) ultimately underwent resection. Operative factors including American Society of Anesthesiology (ASA) score and blood loss were not significantly associated with BMI. Increased BMI was associated with longer operative time, P=0.02. Pathologic factors including proximal tumor location, perineural invasion (PNI), lymphovascular invasion (LVI), positive surgical margins, and positive lymph nodes (LN+) were all associated with a worse OS. Although increased BMI was associated with a lower total lymph node count, P=0.004, the number of LN+ was not associated with BMI. Tumor location, PNI, LVI, margin status, and final pathologic stage were not significantly associated with BMI. Additionally, the use of neoadjuvant or adjuvant chemotherapy was not associated with BMI. Median OS for the group was 22 months. When stratified by BMI, median OS was improved with increased BMI: 21 months for &lt;18.5, 13 months for 18.5-25, 28 months for 25-30, and 34 months for &gt;30, P=0.02. Similarly, disease free survival (DFS) improved with increasing BMI: 2 months for &lt;18.5, 7 months for 18.5-25, 15 months for 25.1-30, and 15 months for &gt;30, P=0.02. Conclusions: Although BMI may impact the technical difficulty of resection for gastric cancer, increasing BMI is not associated with more aggressive disease. In this experience, increased BMI does not adversely impact OS or DFS.
Quality of life and its correlates after pelvic exenteration for gynecologic cancer.
Authors: Kristine A. Donovan, Alexandra Albizu-Rivera, Hye Sook Chon, Robert Michael Wenham
Journal: Journal of Clinical Oncology (2015)

93 Background: Pelvic exenteration (PE) has been performed historically in women with gynecologic cancer for palliation of recurrent disease. With advances in operative methods, PE in the well-selected patient can produce 5-year survival rates as high as 60%. Despite a recent increase in rate of PE performed with curative intent, there is a paucity of data on its long-term physical and emotional effects. We sought to characterize women’s long-term quality of life (QOL) and its correlates after PE for recurrent gynecologic cancer. Methods: We conducted a mixed methods study combining quantitative measurement of QOL and its demographic, clinical and psychological correlates with concurrent qualitative assessment to probe women’s cognitive and behavioral responses to PE. Results: From 2005 to 2014, 85 women underwent PE at our institution; 44% were still alive at study initiation. Among eligible women, 72% completed their participation. Mean age of the sample at time of study participation was 57.3 (SD = 9.5) years (range = 43 to 75) and median time since surgery was 3.0 years (range = .9 to 8). Women’s self-reported global QOL score was average (54.4 (23); range = 33.3 to 100) and the relationship between QOL and current age or time since surgery was not significant (p &gt; .05). Women reported mild sleep disturbance, mild to moderate pain, moderate fatigue and anxiety and severe depressive symptoms. All of the women exceeded the cut-off for clinically significant depressive symptoms. Qualitatively, women described profound negative changes in their physical and emotional well-being after PE. In nearly all of the women, the extended survival after PE helped to buffer the effects of these changes. Conclusions: Results suggest women’s health-related QOL may return to, or near, pre-surgical levels in long-term survivorship but that symptom control is suboptimal. Findings should facilitate more informed decision making prior to PE and suggest targets for clinical intervention to enhance QOL and improve symptom control after PE. This study highlights the need for more comprehensive assessments pre- and post-PE to examine the effects of disease- and PE-related variables, cultural norms and social support on patient-reported outcomes.
Compliance of MAGIC protocol in patients with resectable gastrosophageal (GO) cancer: Tata Memorial Centre (TMC) experience.
Authors: Bhawna Sirohi, Ashish Singh, Alok Gupta, Kedar Deodhar, Mahesh Goel, Shailesh V Shrikhande
Journal: Journal of Clinical Oncology (2014)

154 Background: The perioperative regimen of ECF significantly improved outcome in MAGIC trial. In pts with advanced gastric cancer, oxaliplatin and capecitabine are non-inferior to cisplatin and 5-FU (Cunningham et al, NEJM 2006, 2008). We analysed the compliance, efficacy and toxicity of perioperative EOX (epirubicin, oxaliplatin, capecitabine) in pts with resectable GO cancer. Methods: This is a retrospective analysis of prospectively maintained database of pts with resectable GO cancer txed at TMC with EOX between Jan 2012 to Aug 2013. Pts were planned to receive 3# of neoadjuvant (NA) and 3# of adjuvant EOX (iv epirubicin 50 mg/m 2 D1, oxaliplatin 130 mg/m 2 , on D1, capecitabiine 1250mg/m 2 D1-21 every 21 days. On completion of 3# of EOX, pts were planned to undergo gastrectomy and D2 lymphadenectomy (Shrikhande SV, WJSO 2013). Results: 67 pts (53M/14 F, median age 54 y, 32-76) were treated with NA EOX. Median CEA and Ca 19.9 were 2.76( 0.92-135) and 13.85 (&lt;2 -6,308). 37% pts had signet ring histology and 30% poorly differentiated adenocarcinoma. Pre-operatively 92% pts completed EOX (91% in MAGIC trial); 5 pts did not complete 3# -3 due to grade 3 toxicity, 1 died of sepsis and 1 progressed. Treatment-related mortality was 1/67 (1.4%) compared to 2/237 (0.8%) in MAGIC trial. Response to NA tx was SD 22%, PR 64 %,CR 3% and PD in 6%, not assessable in 3 pts. Surgical resection done in 90% pts (88% in MAGIC); being planned in 5 pts; 6 pts did not undergo surgery—1 lost to follow up, 1 died, 2 PD, 2 inoperable. Resection was R0 in 54 pts and R1 in 2 pts. Median number of nodes dissected was 13 (0-37). 3 pts had pCR. The grade 3 and 4 toxicity was 1% intractable hiccups, 3% neuropathy, 9% diarrhea, 4% febrile neutropenia and 5% hand-foot syndrome—slightly higher than MAGIC reported results. 71% pts received adjuvant chemotherapy compared to 58% in MAGIC trial. Conclusions: In pts with operable GO adenocarcinoma, it is possible to deliver the MAGIC-type perioperative chemotherapy with comparable results in an Indian setting. Unlike MAGIC trial, majority of pts underwent D2 lymphadenectomy.
A comparison of multiple and single cycles of dose-intensive chemotherapy with reinfusion of docetaxel or paclitaxel mobilized peripheral blood progenitor cells in solid tumor
Authors: J. Ren, Y. Zhang, L. Ge, R. Huang, X. Si, H. Wang
Journal: Journal of Clinical Oncology (2005)

834 Background: To compare the clinical outcomes of multiple and single cycle dose-intensive induction therapy with autologous stem cell rescue among 48 patients with recurrent or metastatic solid tumors. Methods: Forty-eight patients(22 male, 26 female, median age was 48, ranged from19 to 73, 20 Breast cancer,6 Ovarian cancer,8 NSCLC,9 SCLC, 4 Seminoma and 1 Synovical carcinoma) were enrolled into the research. Patients were randomized to receive mobilization chemotherapy consisting of docetaxel 110mg/m2 on d1 or paclitaxel 175mg/m2 for 24 hours by continuous infusion. Patients were premedicated with dexamethasone 8mg p.o. every 12h×3 doses starting 24h prior to chemotherapy. The chemotherapy regimen was chosen based on the tumor type regardless of HDC cycle. Twenty-seven patients received 3 cycles of dose-intensive chemotherapy while 21 patients received a single cycle. Results: A significantly higher clinical response rate(CR plus PR) was observed for patients receiving 3 cycles of dose-intensive chemotherapy compared to who received a single cycle(21/27 vs 10/21,p=0.030). The 3 cycle groups also had a significantly higher 2 year survival. At a median follow-up of 40 (36–46) months, the probabilities of survival following single and multiple cycle chemotherapy were 61.90% (95% confidence interval (CI), 38.08%–78.80%) and 81.48% (95% CI, .61.09%–91.84%), respectively. The median event free survival (EFS) and the median overall survival (OS) have not yet been reached. Conclusions: Standard dose docetaxel or paclitaxel, combined with G-CSF, is an effective and well-tolerated mobilization regimen in patients with recurrent or metastatic solid tumors. Multiple cycles high dose chemotherapy has been shown to be feasible and safe in patients with these recurrent or metastatic solid tumors. No significant financial relationships to disclose.
Surgical criteria for femoroacetabular impingement syndrome: a scoping review
Authors: Scott Peters, Alisha Laing, Courtney Emerson, Kelsey Mutchler, Thomas Joyce, Kristian Thorborg, Per Hölmich, Michael Reiman
Journal: British Journal of Sports Medicine (2017)

Background The purpose of this review was to analyse and report criteria used for open and arthroscopic surgical treatment of femoroacetabular impingement syndrome (FAIS). Methods A librarian-assisted computer search of Medline, CINAHL and Embase for studies related to criterion for FAIS surgery was used in this study. Inclusion criteria included studies with the primary purpose of surgery or surgical outcomes for treatment of FAIS with and without labral tear, and reporting criteria for FAIS surgery. Results Diagnostic imaging was a criterion for surgery in 92% of the included studies, with alpha angle the most frequently reported (68% of studies) criterion. Reporting of symptoms was a criterion for surgery in 75%, and special tests a criterion in 70% of studies. Range-of-motion limitations were only a required criterion in 30%, only 12% of studies required intra-articular injection and 44% of studies described previously failed treatment (non-surgical or physiotherapist-led rehabilitation) as a criterion for surgery. Only 56% of included studies utilised the combination of symptoms, clinical signs and diagnostic imaging combined for diagnosis of FAIS as suggested by the Warwick Agreement on FAIS meeting. Conclusion Diagnostic imaging evidence of FAIS was the most commonly reported criterion for surgery. Only 56% of included studies utilised the combination of symptoms, clinical signs and diagnostic imaging for diagnosis of FAIS as suggested by the Warwick Agreement on FAIS meeting, and only 44% of studies had failed non-surgical treatment (and 18% a failed trial of physiotherapy) as a criterion for surgery.
Physical activity and pregnancy: time for guidance in the UK
Authors: Hamish Reid, Ralph Smith, Catherine Calderwood, Charlie Foster
Journal: British Journal of Sports Medicine (2017)

Regular physical activity during pregnancy has a positive impact on pregnancy outcomes and fetomaternal health.1–3 Pregnancy also offers the chance to increase physical activity and sustain this healthy behaviour beyond childbirth. Health behaviours established during childhood can last across the life course, so physical activity interventions during pregnancy may provide a powerful opportunity for population change.4 

Despite these benefits, national recommendations do not exist in the UK for physical activity during pregnancy. In their 2011 physical activity recommendations, the UK Chief Medical Officers (CMOs) emphasised the importance of achieving an active lifestyle across the life course, producing guidelines for four categories: the under 5s, children and young people, adults, and older adults. Pregnancy, however, was omitted from their reviews of evidence and no specific physical activity recommendations exist for this group of women. This omission is to the detriment of antenatal care as recommendations provide an important benchmark …